Professor Xiaofan Zhu: Advancing Collaboration, Standardization, and Innovation to Shape a New Blueprint for Pediatric Leukemia Care | 2026 CACA Western Integrated Oncology Conference

Professor Xiaofan Zhu: Advancing Collaboration, Standardization, and Innovation to Shape a New Blueprint for Pediatric Leukemia Care | 2026 CACA Western Integrated Oncology Conference

To further expand access to high-quality cancer care resources, promote equitable distribution, and enhance the academic and clinical capacity of oncology care in western China and at the grassroots level, the 2026 CACA Western Integrated Oncology Conference was successfully held in Chengdu on April 18, 2026. The conference provided a high-level platform for academic exchange and translational collaboration in oncology.
Leading the Frontier, Shaping the Future | The Inaugural CSH–IACH Joint Symposium on “From Classics to Innovation: Advances in CAR-T Therapy” Successfully Concluded

Leading the Frontier, Shaping the Future | The Inaugural CSH–IACH Joint Symposium on “From Classics to Innovation: Advances in CAR-T Therapy” Successfully Concluded

The diagnosis and treatment of hematologic diseases remain a global challenge. In recent years, with the rapid emergence of innovative therapies such as chimeric antigen receptor T-cell (CAR-T) therapy and the deepening understanding of hematologic disorders, the field has entered a new era.
CSCO Guidelines Conference 2026 | Professor Jun Zhu: Redefining the Future of Lymphoma Care—Guideline Updates Shaping a “China Solution”

CSCO Guidelines Conference 2026 | Professor Jun Zhu: Redefining the Future of Lymphoma Care—Guideline Updates Shaping a “China Solution”

To advance clinical oncology in China, enhance physicians’ diagnostic and research capabilities, and further promote the development and implementation of CSCO guidelines, the Chinese Society of Clinical Oncology (CSCO), together with the Beijing CSCO Clinical Oncology Research Foundation, co-hosted the 2026 CSCO Guidelines Conference in Harbin from April 24 to 25.
CSCO Guidelines Conference 2026 | Professor Jun Ma: Illuminating Standardized Care Through Guidelines—Driving High-Quality Development of Oncology Practice in China

CSCO Guidelines Conference 2026 | Professor Jun Ma: Illuminating Standardized Care Through Guidelines—Driving High-Quality Development of Oncology Practice in China

To advance clinical oncology in China, enhance physicians’ diagnostic and research capabilities, and further promote the development and implementation of CSCO guidelines, the Chinese Society of Clinical Oncology (CSCO), together with the Beijing CSCO Clinical Oncology Research Foundation, co-hosted the 2026 CSCO Guidelines Conference in Harbin from April 24 to 25.
EBMT Global Perspective | Professor Donal McLornan: Defining Remission Criteria and Optimizing Novel Combination Strategies for Bone Marrow Transplantation in MDS/MPN Overlap Syndromes

EBMT Global Perspective | Professor Donal McLornan: Defining Remission Criteria and Optimizing Novel Combination Strategies for Bone Marrow Transplantation in MDS/MPN Overlap Syndromes

Myelodysplastic/myeloproliferative neoplasm (MDS/MPN) overlap syndromes are rare hematologic malignancies characterized by marked clinical heterogeneity and significant diagnostic and therapeutic challenges. Allogeneic hematopoietic stem cell transplantation remains a key treatment option; however, the lack of standardized criteria for assessing post-transplant remission and relapse represents a major unmet clinical need.
EBMT President Professor Ibrahim Yakoub-Agha: A Global Vision for the Future of Therapy—Strengthening Collaboration, Empowering Data, and Standardizing Cellular Therapies

EBMT President Professor Ibrahim Yakoub-Agha: A Global Vision for the Future of Therapy—Strengthening Collaboration, Empowering Data, and Standardizing Cellular Therapies

As a leading global academic organization in transplantation and cellular therapy, the European Society for Blood and Marrow Transplantation (EBMT) has long been committed to advancing clinical research, optimizing patient management, and fostering international collaboration. In the era of rapid progress in cell and gene therapies, EBMT is entering a new phase of opportunity.
EBMT Global Perspective | Professor Francesca Ferrua: Breakthroughs in Autologous Hematopoietic Stem Cell Gene Therapy for WAS—From Concept to Clinical Practice

EBMT Global Perspective | Professor Francesca Ferrua: Breakthroughs in Autologous Hematopoietic Stem Cell Gene Therapy for WAS—From Concept to Clinical Practice

Wiskott–Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency characterized by thrombocytopenia, eczema, and recurrent infections, posing a serious threat to affected children. While allogeneic hematopoietic stem cell transplantation (HSCT) can be curative, it is limited by donor availability, the risk of graft-versus-host disease (GVHD), and conditioning-related toxicity.
EBMT Global Perspective | Professor Annalisa Ruggeri: Cord Blood Transplantation—From Established Platform to Frontier Therapeutic Modality

EBMT Global Perspective | Professor Annalisa Ruggeri: Cord Blood Transplantation—From Established Platform to Frontier Therapeutic Modality

Cord blood transplantation (CBT), an important modality within hematopoietic stem cell transplantation, has faced increasing competition in recent years from alternative donor strategies such as haploidentical transplantation. As a result, the field is undergoing a period of reassessment and transformation. Nevertheless, CBT retains irreplaceable value in selected patient populations, while its potential applications in cell and gene therapy as well as regenerative medicine continue to expand.
Professor Yuankai Shi: Thirty-Five Years of Iterative Innovation—Lymphoma Leading China’s Modernization in Oncology Drug Therapy | 2026 CACA Western Integrative Oncology Conference

Professor Yuankai Shi: Thirty-Five Years of Iterative Innovation—Lymphoma Leading China’s Modernization in Oncology Drug Therapy | 2026 CACA Western Integrative Oncology Conference

As a bellwether for innovation in oncology drug therapy, the evolution of lymphoma treatment reflects the broader trajectory of modernization in Chinese oncology. From the introduction of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in 1992—laying the foundation for chemotherapy—to successive breakthroughs in targeted therapy, immunotherapy, and cellular therapy, China’s lymphoma care has undergone 35 years of transformation, progressing from “following” to “running alongside,” and now to “leading.”
Annual Meeting of the Hematology Branch, CPAM | Professor Yajing Xu: Long-Term Follow-Up Management After Hematopoietic Stem Cell Transplantation—From Digital Solutions to Primary Care Collaboration

Annual Meeting of the Hematology Branch, CPAM | Professor Yajing Xu: Long-Term Follow-Up Management After Hematopoietic Stem Cell Transplantation—From Digital Solutions to Primary Care Collaboration

From April 10 to 11, 2026, the Annual Academic Meeting of the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care (CPAM), together with the “Huatuo Project” MDT Symposium, was held in Changsha. During the meeting, Professor Yajing Xu, Executive Chair and Director of Hematology at Xiangya Hospital, Central South University, was invited by Hematology Frontier to share her insights on the clinical challenges of long-term follow-up after hematopoietic stem cell transplantation (HSCT), standardized management models, and pathways for primary care collaboration. Her discussion aimed to promote the standardization of follow-up systems and improve long-term survival and quality of life for patients.